IGHD

iGRO™ supports individualised GH treatment to children with idiopathic GH deficiency (IGHD) as soon as treatment starts.
It is a web-based tool designed to be used in clinical practice — to predict how much a child may grow in the first and subsequent years of GH therapy.

It can be used to calculate growth predictions for children with idiopathic GH deficiency (IGHD) and provides evidence-based guidance and justification for GH treatment decisions.

iGRO™ prediction algorithms can explain 30-70%1 of variability in growth responses to GH treatment for children with IGHD.

iGRO™ requires standard data that is routinely collected during clinic visits:

  • Birth date
  • Gender
  • Primary diagnosis
  • Birth weight
  • Parents’ heights
  • Height
  • Weight
  • Treatment start date
  • GH dose.

Growth prediction for a child with idiopathic growth hormone deficiency (IGHD) also requires:
 

  • Gestational age 2
  • Maximum GH peak - optional - 2

 

 

1- Ranke, Michael B., et al. "Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency." The Journal of Clinical Endocrinology & Metabolism 84.4 (1999): 1174-1183; Ranke, Michael B., et al. "The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose." The Journal of Clinical Endocrinology & Metabolism 88.10 (2003): 4748-4753.

2- Ranke, Michael B., et al. "Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency." The Journal of Clinical Endocrinology & Metabolism 84.4 (1999): 1174-1183; Ranke MB et al. Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS. J Clin Endocrinol Metab. 2005 Apr;90(4):1966-71.